Patent ID: 8461144
Filing Date: 2013-06-11
Classification: A61P,C07D

Abstract:
1. A method for the treatment in a mammal of a disease associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase comprising administering to the mammal in need thereof at least one compound of the formula (I) wherein R R R H, halogen, (C (C OH, O—R″, NH NHR″, NR″R″ or NH—C(O)—R″, R H, halogen, hydroxy, CN, (C R′, (C R H, halogen, CN, NO (C (C R′, (C (C (C CH(OH)—(C NH NH—R′, NH—SO NH—SO NH—SO NH—C(O)—(C NH—C(O)—R′, C(O)N[(C C(O)OH, or C(O)O—(C R (C (C (C C(O)(C C(O)R′, C(O)—(C R H, Halogen, CN, NO (C O—(C (C R′, (C (C CH(OH)—(C NH NH—R′, NH—SO NH—SO NH—SO SO SO NH—C(O)—(C NH—C(O)—R′, C(O)N[(C C(O)OH, or C(O)O—(C R n is 1, 2, 3 or 4; m is 1, 2, 3, 4 or 5; and L is O or O—(C wherein R′ is (C (C (C R″ is (C (C (C (C (C (C (C (C wherein R (C (C (C (C (C (C (C (C (C wherein in residues R wherein in residues R wherein in residues R C(NH)(NH NH—SO N(C (C O—(C (C wherein the (C or O—(C or wherein (C and wherein aryl or heterocyclyl substituents of (C or their stereoisomeric and/or tautomeric forms and/or their pharmaceutically acceptable salts.